192 related articles for article (PubMed ID: 24142827)
1. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Becker PS; Blayney DW; Cataland SR; Heaney ML; Hudock S; Kloth DD; Kuter DJ; Lyman GH; McMahon B; Rugo HS; Saad AA; Schwartzberg LS; Shayani S; Steensma DP; Talbott M; Vadhan-Raj S; Westervelt P; Westmoreland M; Dwyer M; Ho M;
J Natl Compr Canc Netw; 2013 Oct; 11(10):1266-90. PubMed ID: 24142827
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?
Crawford J; Rodgers GM
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):821-4. PubMed ID: 24853225
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
4. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
7. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA; Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2015 Jan; 13(1):e1-7. PubMed ID: 25583775
[TBL] [Abstract][Full Text] [Related]
8. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
9. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
10. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
11. New treatment options for managing chemotherapy-induced neutropenia.
Valley AW
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ; Bohlke K; Lyman GH; Carson KR; Crawford J; Cross SJ; Goldberg JM; Khatcheressian JL; Leighl NB; Perkins CL; Somlo G; Wade JL; Wozniak AJ; Armitage JO;
J Clin Oncol; 2015 Oct; 33(28):3199-212. PubMed ID: 26169616
[TBL] [Abstract][Full Text] [Related]
14. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
Frampton JE; Keating GM
BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
[TBL] [Abstract][Full Text] [Related]
16. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
17. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
18. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
[TBL] [Abstract][Full Text] [Related]
19. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
Lyman GH
Curr Opin Hematol; 2011 Jan; 18(1):1-10. PubMed ID: 21042215
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
